Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CK2 PMLA nanobioconjugate
- Development stage
- Preclinical
- Lead developer
- Cedars-Sinai
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
anti-CK2 PMLA nanobioconjugate is an experimental nanotherapeutic developed by researchers at Cedars-Sinai Medical Center for the treatment of glioblastoma multiforme (GBM). The drug consists of a biodegradable and non-toxic poly(β-L-malic acid) (PMLA) polymer backbone covalently linked to several functional moieties: targeting antibodies that facilitate crossing the blood-brain barrier (BBB) via transcytosis and binding to tumor cells, a pH-sensitive endosomal escape unit, and antisense oligonucleotides (typically Morpholinos) designed to knockdown the alpha subunit of Casein Kinase 2 (CK2α). CK2 is a serine/threonine protein kinase that is overexpressed in gliomas and acts as a master regulator of prosurvival signaling. By inhibiting CK2, the nanobioconjugate suppresses downstream oncogenic pathways, reduces the expression of cancer stem cell markers (such as c-Myc, CD133, and nestin), and downregulates PD-L1, thereby enhancing therapeutic efficacy and potentially overcoming drug resistance in GBM.
- Other names
- PMLA-anti-CK2PMLA-anti-CK-2PMLA-anti-CK 2AON-CK2-PMLAAON-CK-2-PMLAAON-CK 2-PMLAanti-CK2α PMLA nanobioconjugate
02
Targets
Casein kinase II subunit alpha (CSNK2A1) mRNAEGFR (Epidermal growth factor receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)TFRC (Transferrin Receptor)CK2 (Casein kinase II subunit alpha)
Beyond the preview
Go deeper on anti-CK2 PMLA nanobioconjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CK2 PMLA nanobioconjugate.